本文選題：嵌合抗原受體 + 腫瘤免疫治療��； 參考：《中國腫瘤生物治療雜志》2017年03期

【摘要】：嵌合抗原受體(chimeric antigen receptor,CAR)是單鏈抗體的可變區(qū)(single-chain variable fragments,scFv)和T細胞信號分子的重組融合蛋白,它使T細胞可以通過非MHC限制性方式識別特異性抗原。最近的臨床研究證明,CAR-T細胞在治療B細胞腫瘤中取得了顯著效果。但在目前的臨床應(yīng)用中存在諸多限制,尤其是當腫瘤抗原在正常組織中表達時會造成脫靶效應(yīng)。本文就靶抗原的選擇、脫靶效應(yīng)及相應(yīng)的預(yù)防策略作一綜述,期望這些策略的實施,將會提高CAR-T細胞治療的安全性及有效性,使更多腫瘤患者從中獲益。
[Abstract]:Chimeric antigen receptor carr) is a variable region single-chain variable fragments scFv) and a recombinant fusion protein of T cell signaling molecules, which enables T cells to recognize specific antigens by non-MHC restriction. Recent clinical studies have demonstrated that CAR-T cells are effective in the treatment of B-cell tumors. However, there are many limitations in clinical application, especially when tumor antigens are expressed in normal tissues. In this paper, the selection of target antigen, miss effect and corresponding preventive strategies are reviewed. It is hoped that the implementation of these strategies will improve the safety and effectiveness of CAR-T cell therapy and benefit more cancer patients.
【作者單位】： 河北醫(yī)科大學(xué)第四醫(yī)院腫瘤科;
【分類號】：R730.51
，

本文編號：1830052